Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merieux Institute |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002069 |
To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.
Condition | Intervention |
---|---|
HIV Infections |
Drug: Ditiocarb sodium |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Study of DTC in Patients With AIDS and AIDS Related Complex |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
Concurrent Medication:
Excluded within 3 weeks of study entry:
Patients with the following are excluded:
Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.
United States, Arizona | |
Univ of Arizona / Arizona Cancer Ctr | |
Tucson, Arizona, United States, 85724 | |
United States, California | |
San Francisco AIDS Clinic / San Francisco Gen Hosp | |
San Francisco, California, United States, 941102859 | |
Portion Med Group | |
Sherman Oaks, California, United States, 91403 | |
USC School of Medicine / Norris Cancer Hosp | |
Los Angeles, California, United States, 90033 | |
United States, Florida | |
Florida Keys Memorial Hosp | |
Key West, Florida, United States, 33040 | |
United States, New York | |
SUNY / Health Sciences Ctr at Brooklyn | |
Brooklyn, New York, United States, 11203 | |
United States, North Carolina | |
Duke Univ Med Ctr | |
Durham, North Carolina, United States, 27710 | |
United States, Texas | |
Dr Gary Brewton | |
Houston, Texas, United States, 77027 |
Study ID Numbers: | 010A |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002069 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Ditiocarb Acquired Immunodeficiency Syndrome AIDS-Related Complex |
Anti-Infective Agents Sexually Transmitted Diseases, Viral Ditiocarb Immunologic Factors Acquired Immunodeficiency Syndrome Adjuvants, Immunologic AIDS-Related Complex |
Antiviral Agents Immunologic Deficiency Syndromes Virus Diseases HIV Infections Sexually Transmitted Diseases Chelating Agents Retroviridae Infections |
Anti-Infective Agents RNA Virus Infections Sexually Transmitted Diseases, Viral Ditiocarb Slow Virus Diseases Molecular Mechanisms of Pharmacological Action Immunologic Factors Immune System Diseases Physiological Effects of Drugs Acquired Immunodeficiency Syndrome Adjuvants, Immunologic AIDS-Related Complex |
Infection Antiviral Agents Pharmacologic Actions Immunologic Deficiency Syndromes Virus Diseases HIV Infections Therapeutic Uses Sexually Transmitted Diseases Lentivirus Infections Chelating Agents Retroviridae Infections |